Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682264 · ClinicalTrials.gov registry record · Phase 3
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Cassiopea SpA.
- Completed
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
- 20
- Study locations
NCT02682264 is a Phase 3 study of Acne Vulgaris that has completed, run by Cassiopea SpA. The registered enrollment target is 609 participants, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02682264, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Cassiopea SpA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.
Conditions Studied
Interventions
- DRUG CB-03-01 cream, 1%
Study Locations (20)
California
- Center for Dermatology and Laser Surgery - Sacramento
- Rady Childrens Hospital, Pediatric and Adolescent Dermatology - San Diego
- Southern California Dermatology - Santa Ana
- Clinical Science Institute - Santa Monica
- Memorial Research Medical Clinic dba / Orange County Research Center - Tustin
Florida
- Study Protocol, Inc. - Boynton Beach
- Tory Sullivan, M.D., P.A. - North Miami Beach
- Belleair Research Center - Pinellas Park
- Meridien Research - St. Petersburg
- MOORE Clinical Research, Inc. - Tampa
Arkansas
- Johnson Dermatology - Fort Smith
- Gary M. Petrus, MD PA - Little Rock
Indiana
- Shideler Clinical Research Center - Carmel
- The Indiana Clinical Trials Center - Plainfield
Colorado
- Horizons Clinical Research Center, LLC - Denver
Georgia
- MedaPhase, Inc. - Newnan
Illinois
- Arlington Dermatology - Arlington Heights
Kansas
- Kansas City Dermatology, PA - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682264
The ClinicalTrials.gov registry entry for NCT02682264 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (129% higher). The listed sponsor is Cassiopea SpA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which CB-03-01 cream, 1% is the first listed.
NCT02682264 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02682264 about?
NCT02682264 is a clinical study titled "An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris". The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.
What is the current status of trial NCT02682264?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2016-03-09. Estimated completion is 2018-08-31.
What conditions does trial NCT02682264 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02682264?
The interventions under investigation include: CB-03-01 cream, 1% (DRUG).
Who is sponsoring clinical trial NCT02682264?
This trial is sponsored by Cassiopea SpA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02682264 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.